Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 CAD | +0.70% | +0.17% | +10.40% |
Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Sales 2024 * | 345M 252M | Sales 2025 * | 354M 259M | Capitalization | 580M 424M |
---|---|---|---|---|---|
Net income 2024 * | 3M 2.19M | Net income 2025 * | 2M 1.46M | EV / Sales 2024 * | 1.68 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
63.7
x | P/E ratio 2025 * |
58.8
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.56% |
Latest transcript on Knight Therapeutics Inc.
1 day | +0.70% | ||
1 week | +0.17% | ||
Current month | +8.11% | ||
1 month | +5.52% | ||
3 months | +2.32% | ||
6 months | +29.35% | ||
Current year | +10.40% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert N. Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.73 | +0.70% | 41,264 |
24-04-25 | 5.69 | -0.52% | 59,340 |
24-04-24 | 5.72 | -1.72% | 22,021 |
24-04-23 | 5.82 | +0.52% | 26,122 |
24-04-22 | 5.79 | +1.22% | 40,198 |
Delayed Quote Toronto S.E., April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.40% | 424M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- GUD Stock